Roderick Corriveau, Ph.D.

Job Title
Program Director
Photo of Roderick Corriveau
Division of Neuroscience
Cluster, Section, or Program
Neurodegeneration, Dementia, and Repeat Expansion Disorders
Areas of Interest

Portfolio: Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) Program Lead; Point of Contact for Vascular Contributions to Cognitive Impairment and Dementia (VCID), for example Vascular Cognitive Impairment (VCI), Vascular Dementia (VaD), Cerebral Amyloid Angiopathy (CAA), and CADASIL    

Additional Keywords: Small cerebral vessel diseases (e.g. atherosclerosis, arteriolosclerosis); post-stroke VCID; multi-infarct dementia; TBI with vascular lesions that lead to dementia; heart failure related to cognitive decline; cardiovascular and cerebrovascular dysfunction; anti-beta-amyloid immunotherapy


Dr. Roderick Corriveau joined the NINDS as a Program Director in 2010 and is responsible for the NINDS Vascular Contributions to Cognitive Impairment and Dementia (VCID) portfolio. He is the NIH Lead for the Alzheimer’s Disease-Related Dementias (ADRD) Summits and planning effort, including in 2013, 2016 and 2019. These summits, which are responsive to the National Plan to Address Alzheimer’s Disease and set national priorities to guide dementia research through 2025, are triennial and complement the NIA-led AD and Dementia Care summits. Dr. Corriveau received his bachelor’s degree in biochemistry from Simon Fraser University, and his Ph.D. in Neurosciences from the University of California San Diego. His graduate and postdoctoral studies focused on gene expression and the role of electrical activity in neural circuit development. As an HHMI Postdoctoral Associate with Carla Shatz at UC Berkeley, he contributed to the discovery of a role for immune molecules in synaptic development and change. Dr. Corriveau was an Assistant Professor at the LSU Health Sciences Center where he investigated the role of NMDA receptor-dependent neural signaling in gene expression and naturally occurring neuronal cell death. Prior to joining NINDS, he was at the Coriell Institute for Medical Research.